Roche signs $1.1 billion stapled peptide deal with Aileron
This article was originally published in Scrip
Executive Summary
Roche is to pay Aileron Therapeutics up to $1.1 billion in milestones to develop novel stapled peptide therapeutics against five undisclosed targets.